Guidelinehigh evidence
Cardiovascular, kidney related, and weight loss effects of therapeutics for type 2 diabetes: a living clinical practice guideline.
BMJ (Clinical research ed.)·August 14, 2025·PMID 40813129
Why it mattersThis guideline helps clinicians match diabetes medications to cardiorenal risk rather than using a one-size-fits-all approach. It is especially relevant when deciding whether newer agents should be used primarily for event reduction, kidney protection, or weight loss.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled